Democratic Congressional Sweep Sets Stage for Sweeping Federal Health Policy Overhaul

Democrats’ decisive sweep of the U.S. House and Senate in Tuesday’s elections is poised to reshape federal health policy, setting the stage for oversight investigations, a legislative push to reverse cuts to the Affordable Care Act and Medicaid, and a renewed focus on lowering costs such as insurance premiums and drug prices.

The sweeping victories enable Democrats to argue that voters — who ranked healthcare affordability as a top concern in pre-election surveys — have issued a clear mandate to overturn the historic cuts to public health programs enacted by President Donald Trump and Republicans.

The breadth of their success, including victories by Senator-elect Abdul El-Sayed of Michigan and other progressives, is likely to embolden Democrats to pursue ambitious proposals such as expanding Medicare — the federal insurance program for those 65 and older — to cover all Americans, positioning the party as the champion of lower healthcare costs ahead of the 2028 presidential election.

However, party leaders will need cooperation from Trump to advance any healthcare agenda. Although he wields veto power, he may be inclined to broker legislative deals as he seeks to cement his legacy and deflect fallout from investigations into his administration’s handling of the conflict with Iran, mass deportations, contracting scandals, and other controversies.

As of Wednesday afternoon, The Associated Press projected Democrats would win at least 237 of 435 House seats and at least 54 Senate seats. Several key races remained unresolved, including Senate contests in Alaska and Mississippi.

As election results continued to arrive early Wednesday, Trump told Politico in a phone interview that he had spoken with Democratic leaders and acknowledged that voters had sent a message that he must work with them “to make sure things go well for our country.”

“I don’t want to just be sitting there for two years vetoing everything,” Trump said. “They want to see things happen, too.”

It remains to be seen how Trump’s newly conciliatory stance will translate into reversing GOP-led changes, such as new work requirements for many adults enrolled in Medicaid, the state-federal program for low-income and disabled individuals. Republicans had touted their overhaul of Medicaid and other health program changes enacted through their One Big Beautiful Bill Act as signature achievements in the midterm campaigns.

Democrats will also need to balance their policy ambitions with their desire to investigate a host of concerns surrounding the nation’s top health official, Robert F. Kennedy Jr., who has dismantled U.S. vaccine recommendations, gutted federal health agency staff, and cut public health funding.

“Democrats will put forward an expansive healthcare agenda, including reversal of cuts to Medicaid and the ACA, but achieving all of that will be impossible with President Trump still in the White House,” said Larry Levitt, executive vice president at KFF, a health information nonprofit that includes KFF Health News.

New Year, New Congress, New Majority

An early priority for Democrats in 2027 will likely be a legislative push to restore the enhanced subsidies that reduced premiums for millions of Obamacare enrollees. Those subsidies, created during the COVID-19 pandemic as part of economic relief packages, expired last year after Trump and the Republican-controlled Congress declined to extend them.

Rep. Hakeem Jeffries of New York, the current Democratic House leader widely expected to become speaker, told CNN on Wednesday that the party should reinstate the subsidies to assist struggling families.

“My guess is it would be rolled into a broader budget negotiation or package that may or may not involve other healthcare priorities, like restoring Medicaid cuts or other Democratic priorities,” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University.

If they act decisively, said Leslie Dach, chair of the Democratic-aligned advocacy group Protect Our Care, Democrats could both renew the ACA’s expired subsidies and extend the enrollment period for 2027 coverage, which ends in most states on Jan. 15, shortly after the new Congress is sworn in.

They would need to act within days of assuming control, Dach said.

“Congress will be sworn in during open enrollment, at a time when people will be forced to make difficult and horrific choices about their healthcare, given the further premium increases due to Republican policies,” he said.

Premiums for Affordable Care Act benchmark plans are projected to increase by an average of 13% for 2027, according to KFF researchers.

With Congress likely to pass another short-term government funding bill in December, the stage will be set for incoming lawmakers to battle over Medicaid spending cuts in the spring, said Rodney Whitlock, a healthcare consultant who previously worked for Republicans in Congress.

Democrats — many of whom made healthcare affordability a centerpiece of their campaigns — are now well positioned to place that issue at the center of negotiations with Trump over federal spending.

“If you’ve got the opportunity for a battle in March over fiscal year funding — and Democrats picking and choosing what they want to make this first battle about with a unified, controlled Congress with the president — damn, doesn’t it scream healthcare?” Whitlock said. “Doesn’t it scream repeal or delay all the Medicaid cuts?”

Allison Orris, a partner at Manatt, advised clients before Election Day not to count on any changes — even with Democrats in control.

“The White House ultimately will have to sign any legislation, and HR 1 was a signature accomplishment. It will cost money to undo or even just delay changes that were enacted in 2025,” she said, referring to the One Big Beautiful Bill Act.

What Else Could Happen?

Trump is likely to continue relying heavily on executive actions to shape health policy from the White House. Meanwhile, Democrats will use their control of Congress to exercise oversight of the Trump administration and the Department of Health and Human Services.

Jeffries, the House Democratic leader, has promised the party will “hold the crooks accountable” by pursuing aggressive oversight of the Trump administration. Democrats on the House Committee on Oversight and Government Reform released a report in June previewing investigations they may launch.

Specifically, Democrats want to zero in on clandestine drug-pricing deals Trump has made with pharmaceutical companies in exchange for relief from certain tariffs. No contracts or paperwork for these agreements have been made public. They also allege he benefited from stock price increases when companies received exemptions from Medicare price negotiation under the 2025 GOP tax and spending law.

By taking control of congressional committees, Democrats will gain subpoena power, a critical investigatory tool. However, it is unclear whether they can successfully compel documents from the government or companies, because the Department of Justice, under Trump, is largely responsible for enforcing subpoenas. Nevertheless, subpoenas are likely to be issued for investigations into tariffs Trump has imposed and threatened on prescription drugs.

Democratic congressional leaders will also be able to file lawsuits against the Trump administration to challenge the White House’s actions.

Democrats have also signaled plans to probe scientific decision-making on controversial issues such as allowing more sales of flavored vapes and White House promotion of the herbicide glyphosate — and any connections these actions have to political contributions from companies.

Other industry oversight by Democrats would likely focus on preauthorization denials by insurance companies; scrutiny of Medicare Advantage, the alternative to traditional Medicare run by commercial insurers; and the use of artificial intelligence in medical decision-making.

Also looming is a broader discussion of universal health coverage, including partial steps such as expanding traditional Medicare benefits to include dental and hearing care and lowering the Medicare eligibility age to 60 or younger.

Expanding the program to cover all Americans faces formidable challenges, even if Trump were open to it. Much of the nation’s healthcare industry — including doctors, hospitals, and insurers — would surely fight any legislative effort, and Democrats have never seriously grappled with the enormous implications of such a proposal for the federal budget, taxes, medical care, and broader society.

Other possible initiatives include implementing a federal solution to address the 10 states that have opted not to fully expand Medicaid to cover lower-income adults, as well as allowing children to remain on their parents’ health insurance policies beyond age 26.

Because the new Congress is not set to be sworn in until January, a lame-duck session through year’s end, in which Republicans retain the majority, will focus on funding the federal government and addressing some health programs set to expire.

One major move Congress is expected to make soon is a confirmation vote for Heidi Overton to lead the Food and Drug Administration, which has been without a permanent leader since May. Her confirmation is not guaranteed, however, with Democrats uniformly opposed.

A handful of Republicans have questioned whether she will sufficiently restrict access to medication abortion, while some moderate Republicans have also expressed concerns — including Sen. Bill Cassidy of Louisiana, who questioned whether Overton supports the administration’s changes to vaccine recommendations.

Cassidy lost his seat after Trump endorsed a Republican primary challenger, Rep. Julia Letlow, who narrowly won election to the Senate on Tuesday.

Other issues enjoy bipartisan support, such as preventing cuts to Medicare payments to doctors scheduled to begin Jan. 1, and making fixes to the No Surprises Act, a 2022 federal law that protects consumers with private insurance from unexpected out-of-network charges. But movement on these fronts would be a long shot.

“Everyone gets hyped up for lame ducks, and they’re always a disappointment,” said Doug Holtz-Eakin, an economist and president of the conservative-leaning American Action Forum.

But come January, Washington will need to find a way to work together to make healthcare more affordable — or risk the ire of voters who have consistently ranked it as one of their top issues in recent elections, noted Matt Hogan, a partner at Impact Research, a Democratic polling firm.

Taken together, healthcare and prescription drug prices are the top cost concern for voters over 50, he noted.

Reining in prescription drug prices could be an area of bipartisan support — including from Trump, who claimed ahead of the midterms that lowering some drug prices was one of his administration’s greatest achievements. Both parties have proposed limits on pharmacy benefit managers, which negotiate drug prices on behalf of insurers and employers; patent restrictions for certain drugs; and benchmarking U.S. drug prices against those in other countries.

“This is the third-straight election that’s really been focused on affordability,” Hogan said. “If members of Congress haven’t got the message yet, I expect them to now.”

Source link